share_log

UroGen Pharma Ltd | 8-K: UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

UroGen Pharma Ltd | 8-K: UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights

乌龙制药 | 8-K:UroGen Pharma 提前完成 UGN-102 保密协议的提交和报告 2024 年第二季度财务业绩和业务亮点
美股SEC公告 ·  2024/08/13 20:07
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息